KalVista
KALV
Performance
About KalVista
KalVista Pharmaceuticals is a biopharmaceutical company focused on developing oral small-molecule medicines to treat hereditary angioedema (HAE) and related conditions. The company aims to advance science to empower everyday lives by addressing unmet needs in HAE through oral inhibitors and a focused pipeline. KalVista operates in the biotechnology and pharmaceutical sector with programs that include clinical trials and investor activities, and highlights its commitment to patients, caregivers, and healthcare professionals. The organization emphasizes translating scientific advances into patient-friendly, on-demand treatment options.
Recent News
Pharma and Biotech M&As 2026 Deal Watcher
In Chiesi’s Biggest M&A Deal yet, Pharma Buys HAE Company KalVista
Intellia’s In‑Vivo CRISPR Therapy Clears Phase 3, Prompting $1.9 B Chiesi Deal
Angelini Inks $4.1B Catalyst Buy to Enter US Rare Disease Market
Chiesi to Acquire KalVista for $1.9 B, Adding First Oral HAE Therapy
Top Biotech Deals in April 2026
Chiesi Group to Acquire KalVista Pharmaceuticals for ~$1.9B
CVC and GBL Unveil €10.7 Bn Take‑Private Offer for Recordati
Kalvista Pharmaceuticals Inc (KALV) Q1 2026 Earnings Call Transcript
Chiesi Snaps up KalVista for $1.9B, Betting Big on Rare Disease Med Ekterly